Back to results
US 12,498,382 B2Granted
Biomarkers for vitiligo
AssigneeIncyte Corporation
InventorsMichael D. Howell, Sherry Owens, Beth Rumberger, Huiqing Liu
Life of this patent
Estimating the term…
Abstract
Biomarkers are provided that are associated with or predictive of a subject's responsiveness to a JAK inhibitor. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing vitiligo.
Claims13
A method of treating a human subject having, suspected of having, or at risk of developing vitiligo, comprising:
- measuring, in a first biological sample obtained from the human subject prior to administering a JAK inhibitor, the concentration of CXCL9, CXCL10, CCL19, IL2-RA, CCL18, IL12, MMP12, GZMB, and/or Gal-9;
- administering the JAK inhibitor to the human subject;
- and
- measuring, in a second biological sample obtained from the human subject after administering the JAK inhibitor, a reduced concentration, as compared to the first biological sample, of CXCL9, CXCL10, CCL19, IL2-RA, CCL18, IL12, MMP12, GZMB, and/or Gal-9,
- wherein the JAK inhibitor is ruxolitinib or a pharmaceutically acceptable salt thereof.
2 more elements
Dependencies are inferred from the claim text.